Biosyent Inc (BIOYF)
7.49
0.00 (0.00%)
USD |
OTCM |
Jul 03, 16:00
Biosyent Enterprise Value: 69.24M for July 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 03, 2024 | 69.24M |
| July 02, 2024 | 69.24M |
| July 01, 2024 | 69.24M |
| June 28, 2024 | 69.24M |
| June 27, 2024 | 70.75M |
| June 26, 2024 | 70.75M |
| June 25, 2024 | 69.38M |
| June 24, 2024 | 70.75M |
| June 21, 2024 | 67.62M |
| June 20, 2024 | 65.77M |
| June 18, 2024 | 64.14M |
| June 17, 2024 | 62.75M |
| June 14, 2024 | 63.57M |
| June 13, 2024 | 61.25M |
| June 12, 2024 | 61.83M |
| June 11, 2024 | 59.97M |
| June 10, 2024 | 59.97M |
| June 07, 2024 | 59.97M |
| June 06, 2024 | 59.86M |
| June 05, 2024 | 59.68M |
| June 04, 2024 | 59.68M |
| June 03, 2024 | 59.68M |
| May 31, 2024 | 59.63M |
| May 30, 2024 | 59.35M |
| May 29, 2024 | 59.16M |
| Date | Value |
|---|---|
| May 28, 2024 | 63.10M |
| May 24, 2024 | 58.82M |
| May 23, 2024 | 58.35M |
| May 22, 2024 | 58.35M |
| May 21, 2024 | 59.16M |
| May 20, 2024 | 63.57M |
| May 17, 2024 | 59.86M |
| May 16, 2024 | 54.99M |
| May 15, 2024 | 54.92M |
| May 14, 2024 | 53.76M |
| May 13, 2024 | 55.85M |
| May 10, 2024 | 55.85M |
| May 09, 2024 | 55.85M |
| May 08, 2024 | 55.93M |
| May 07, 2024 | 55.93M |
| May 06, 2024 | 55.93M |
| May 03, 2024 | 56.40M |
| May 02, 2024 | 55.92M |
| May 01, 2024 | 55.92M |
| April 30, 2024 | 55.82M |
| April 29, 2024 | 55.93M |
| April 26, 2024 | 55.35M |
| April 25, 2024 | 55.35M |
| April 24, 2024 | 55.35M |
| April 23, 2024 | 55.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
12.01M
Minimum
Mar 18 2020
78.95M
Maximum
Jun 24 2021
50.83M
Average
51.66M
Median
Sep 30 2021
Enterprise Value Benchmarks
| Acasti Pharma Inc | 4.253M |
| Aurinia Pharmaceuticals Inc | 431.83M |
| Edesa Biotech Inc | 10.77M |
| Lexaria Bioscience Corp | 28.85M |
| Xenon Pharmaceuticals Inc | 2.026B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.311M |
| Revenue (Quarterly) | 5.734M |
| Total Expenses (Quarterly) | 4.184M |
| EPS Diluted (Quarterly) | 0.1105 |
| Gross Profit Margin (Quarterly) | 79.44% |
| Profit Margin (Quarterly) | 22.87% |
| Earnings Yield | 5.80% |
| Operating Earnings Yield | 6.72% |
| Normalized Earnings Yield | 5.812 |